IDEAYA Biosciences, Inc. 8-K

What Happened
IDEAYA Biosciences (filed 8-K April 13, 2026) and Servier announced topline results from OptimUM‑02, a global Phase 2/3 registrational trial evaluating darovasertib combined with crizotinib in first‑line HLA‑A*02:01‑negative metastatic uveal melanoma (mUM). As of the January 23, 2026 cutoff, 313 patients were enrolled in the Phase 2b/3 portion (210 in the darovasertib combination arm; 103 in the investigator‑choice therapy [ICT] arm). The darovasertib combination met the primary endpoint: blinded independent central review (BICR) showed a 58% reduction in risk of progression (HR 0.42; 95% CI 0.30–0.59; p<0.0001) with median progression‑free survival (PFS) of 6.9 months vs. 3.1 months for ICT. Objective response rate (ORR) by BICR was 37.1% vs. 5.8% (p<0.0001); five complete responses observed in the darovasertib arm. Median duration of response (DOR) in the combination arm was 6.8 months. Overall survival (OS) data are not mature but show an early trend favoring the combination.

Key Details

• Trial cut‑off date: January 23, 2026; total Phase 2b/3 enrolled = 313 patients (210 combo / 103 ICT).
• Primary endpoint: PFS by BICR — HR 0.42 (95% CI 0.30–0.59), median PFS 6.9 vs. 3.1 months, p<0.0001.
• Secondary/non‑primary: ORR 37.1% (combo) vs. 5.8% (ICT); 5 complete responses in combo arm; median DOR 6.8 months.
• Safety: generally well tolerated; most common Grade 3+ events included diarrhea, syncope, hypotension; treatment‑related serious adverse events in the single‑digit percent range.
• Next steps: IDEAYA targets submission of a New Drug Application (NDA) to the FDA in the second half of 2026 and plans additional data presentation at a major medical conference in 2026.

Why It Matters
These topline results provide the efficacy data IDEAYA plans to use to support an initial U.S. NDA filing (target H2 2026). A positive registrational PFS readout and a materially higher ORR versus standard immunotherapy in this first‑line, HLA‑A*02:01‑negative mUM population are material near‑term catalysts for the company (regulatory submission and upcoming conference disclosure). Investors should note OS is immature and safety signals, while described as manageable, will be reviewed in full detail in forthcoming data releases and regulatory filings. The company also reiterated standard forward‑looking risk disclosures and referenced its recent 2025 Form 10‑K for additional risk factors.